Alnylam Pharmaceuticals (ALNY)

$236.01 -0.21 (-0.09%)
Market Cap 31.61B
Revenue (ttm) 3.71B
Net Income (ttm) 313.75M
EPS (ttm) N/A
PE Ratio 42.62
Forward PE 34.82
Profit Margin 8.45%
Debt to Equity Ratio 0.00
Volume 2,137,200
Avg Vol 1,867,086
Day's Range N/A - N/A
Shares Out 133.81M
Stochastic %K 68%
Beta 0.30
Analysts Strong Sell
Price Target $376.28

Company Profile

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products i...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 551 8200
Fax: 617 551 8101
Address:
675 West Kendall Street, Henri A. Termeer Square, Cambridge, United States
jewell69
jewell69 Aug. 24 at 5:34 PM
$ALNY willing 2 pay up for it. trying 2 by 15 at 288.28. as of 1:33 pm edt on 8/24 b a 231.95 x 232.13 lo so far today 228.59 08/14/2026 Sell ALNY ALNYLAM PHARMACEUTICALS 18 $227.80 $0.08 $4,100.32 More 08/13/2026 Buy ALNY ALNYLAM PHARMACEUTICALS 18 $226.12
0 · Reply
MaxDanger
MaxDanger Aug. 24 at 2:40 PM
$ALNY if the hypertension data is good next weekend, this may rocket back to $300+.
0 · Reply
Iskill1
Iskill1 Aug. 24 at 1:24 PM
$QQQ holdings on my radar before the open Bullish: $MDLZ — trend-aligned DB candidate. Watching 63.57 support; structural target remains near 67.08. $CSX — reversal/reclaim watch after Deep Selling Exhaustion. Watching 51.44 and acceptance above 51.75–52. Bearish: $ALNY — the only Tier-2 bearish result from the Nasdaq-100 scan. Rally-fade watch only; the rebound must fail before the bearish thesis becomes active. These are conditional watch candidates, not automatic entries.
0 · Reply
StockBraker
StockBraker Aug. 24 at 12:51 PM
$ALNY https://www.businesswire.com/news/home/20260822840046/en/Alnylam-to-Present-New-Data-Reinforcing-Strength-in-RNAi-Powered-TTR-Silencing-and-Continued-Progress-in-Hypertension-at-ESC-Congress-2026
0 · Reply
ShirleyThames338
ShirleyThames338 Aug. 24 at 9:42 AM
$BIIB $SUNB $EXR $ALNY $TECK Biogen remains focused on neurological therapies, SunBelt-related exposure remains tied to regional financial conditions, Extra Space Storage benefits from self-storage demand, Alnylam advances RNAi medicines, and Teck benefits from copper and metallurgical-coal prices. I'm watching clinical milestones, credit conditions, occupancy, drug launches, and metals prices.
0 · Reply
sampeper
sampeper Aug. 21 at 10:33 AM
$ALNY Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to "Strong-Buy" at BMO Capital Markets https://www.marketbeat.com/instant-alerts/alnylam-pharmaceuticals-nasdaqalny-upgraded-to-strong-buy-at-bmo-capital-markets-2026-08-20/
0 · Reply
akinyo
akinyo Aug. 20 at 10:26 PM
$ALNY Back to $200 so I can pick up 100 more shares pretty please 🥺
0 · Reply
hi_tech_lowlife
hi_tech_lowlife Aug. 20 at 4:30 PM
Biotech Is Booming, But These 2 Stocks Missed the Memo $IBB $MRNA $MRK $INSM $ALNY https://www.benzinga.com/trading-ideas/movers/26/08/61336082/biotech-is-booming-but-these-2-stocks-missed-the-memo
0 · Reply
jewell69
jewell69 Aug. 20 at 4:21 PM
$ALNY trying 2 b 18 232 12:18 pm edt 8/20. we would b paying up for it. recent trade history. soooo lucky we sold b4 earnings, and it fell out of bed. 07/27/2026 Sell ALNY ALNYLAM PHARMACEUTICALS 29 $282.96 $0.18 $8,205.66 08/14/2026 Sell ALNY ALNYLAM PHARMACEUTICALS 18 $227.80 $0.08 $4,100.32 More 08/13/2026 Buy ALNY ALNYLAM PHARMACEUTICALS 18 $226.12 -$4,070.16
0 · Reply
ManuelLemon952
ManuelLemon952 Aug. 20 at 7:38 AM
$BIIB $SUNB $EXR $ALNY $TECK Biogen remains focused on neurological therapies, SunBelt-related exposure remains tied to regional financial conditions, Extra Space Storage benefits from self-storage demand, Alnylam advances RNAi medicines, and Teck benefits from copper and metallurgical-coal prices. I'm watching clinical milestones, credit conditions, occupancy, drug launches, and metals prices.
0 · Reply
Latest News on ALNY
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026

Aug 24, 2026, 8:33 AM EDT - 14 hours ago

Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026

ALNY

ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Aug 5, 2026, 4:28 AM EDT - 19 days ago

ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

ALNY

Alnylam Pharmaceuticals Earnings Call Transcript: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 25 days ago

Alnylam Pharmaceuticals Earnings Call Transcript: Q2 2026

Alnylam Pharmaceuticals Earnings release: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 25 days ago

Alnylam Pharmaceuticals Earnings release: Q2 2026

Alnylam Pharmaceuticals Quarterly report: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 25 days ago

Alnylam Pharmaceuticals Quarterly report: Q2 2026

Alnylam Pharmaceuticals Slides: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 25 days ago

Alnylam Pharmaceuticals Slides: Q2 2026

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

Jul 30, 2026, 8:00 AM EDT - 25 days ago

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

ALNY

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Jul 16, 2026, 8:00 AM EDT - 5 weeks ago

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

ALNY

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

Jul 15, 2026, 3:30 AM EDT - 5 weeks ago

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

ALNY

AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.

Jul 9, 2026, 7:38 AM EDT - 6 weeks ago

AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.

ALNY AZN IONS

Alnylam Pharmaceuticals Transcript: Study update

Jun 25, 2026, 11:00 AM EDT - 2 months ago

Alnylam Pharmaceuticals Transcript: Study update

Alnylam Pharmaceuticals Slides: Study update

Jun 25, 2026, 11:00 AM EDT - 2 months ago

Alnylam Pharmaceuticals Slides: Study update

Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform

Jun 25, 2026, 9:00 AM EDT - 2 months ago

Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform

ALNY

The Healthcare M&A Wave

Jun 17, 2026, 12:30 PM EDT - 2 months ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX

Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

Jun 12, 2026, 9:00 AM EDT - 2 months ago

Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

ALNY

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

Jun 10, 2026, 7:47 AM EDT - 2 months ago

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

ALNY

Alnylam Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 11:20 AM EDT - 2 months ago

Alnylam Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500

Jun 8, 2026, 5:06 PM EDT - 2 months ago

Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500

ALAB ALNY BE RDDT

Alnylam, Inceptive sign up to $2 billion AI drug discovery deal

Jun 3, 2026, 6:05 PM EDT - 2 months ago

Alnylam, Inceptive sign up to $2 billion AI drug discovery deal

ALNY

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

Jun 3, 2026, 4:45 PM EDT - 2 months ago

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

ALNY

Alnylam Pharmaceuticals Transcript: AGM 2026

May 20, 2026, 10:30 AM EDT - 3 months ago

Alnylam Pharmaceuticals Transcript: AGM 2026

Alnylam Issues 2025 Corporate Responsibility Report

May 19, 2026, 8:30 AM EDT - 3 months ago

Alnylam Issues 2025 Corporate Responsibility Report

ALNY

Alnylam Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 1:40 PM EDT - 3 months ago

Alnylam Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

May 12, 2026, 2:30 AM EDT - 3 months ago

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

ALNY

Alnylam to Webcast Presentations at Upcoming Investor Conferences

May 7, 2026, 8:00 AM EDT - 3 months ago

Alnylam to Webcast Presentations at Upcoming Investor Conferences

ALNY

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

May 4, 2026, 8:30 AM EDT - 4 months ago

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

ALNY

Alnylam Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 4 months ago

Alnylam Pharmaceuticals Earnings Call Transcript: Q1 2026

Alnylam Pharmaceuticals Quarterly report: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 4 months ago

Alnylam Pharmaceuticals Quarterly report: Q1 2026

Alnylam Pharmaceuticals Slides: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 4 months ago

Alnylam Pharmaceuticals Slides: Q1 2026

Alnylam Pharmaceuticals Earnings release: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 4 months ago

Alnylam Pharmaceuticals Earnings release: Q1 2026

Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress

ALNY

Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

ALNY

An S&P 500 change may be imminent. These stocks are leading contenders to join the index.

Apr 6, 2026, 2:14 PM EDT - 5 months ago

An S&P 500 change may be imminent. These stocks are leading contenders to join the index.

IVV SPXL SPY SSO UPRO VOO ALNY

Alnylam Pharmaceuticals Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 5 months ago

Alnylam Pharmaceuticals Proxy statement: Proxy filing

Alnylam Pharmaceuticals Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 5 months ago

Alnylam Pharmaceuticals Proxy statement: Proxy filing

New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

Mar 30, 2026, 1:00 PM EDT - 5 months ago

New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

ALNY

Alnylam Pharmaceuticals Transcript: Status update

Mar 24, 2026, 9:30 AM EDT - 5 months ago

Alnylam Pharmaceuticals Transcript: Status update

Alnylam Pharmaceuticals Press release: Status update

Mar 24, 2026, 9:30 AM EDT - 5 months ago

Alnylam Pharmaceuticals Press release: Status update

Alnylam Pharmaceuticals Slides: Status update

Mar 24, 2026, 9:30 AM EDT - 5 months ago

Alnylam Pharmaceuticals Slides: Status update

Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis

Mar 24, 2026, 9:00 AM EDT - 5 months ago

Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis

ALNY

Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

Mar 24, 2026, 7:30 AM EDT - 5 months ago

Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

ALNY

How Alnylam Stock Weathers Market Shocks

Mar 11, 2026, 11:55 AM EDT - 5 months ago

How Alnylam Stock Weathers Market Shocks

ALNY

Alnylam to Webcast TTR Investor Webinar

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Alnylam to Webcast TTR Investor Webinar

ALNY

Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments

Mar 5, 2026, 9:10 AM EST - 6 months ago

Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments

ALNY TNYA

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

Mar 5, 2026, 8:30 AM EST - 6 months ago

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

ALNY TNYA

Alnylam Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:10 AM EST - 6 months ago

Alnylam Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 10:00 AM EST - 6 months ago

Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference

ALNY

Alnylam Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 12, 2026, 8:30 AM EST - 6 months ago

Alnylam Pharmaceuticals Earnings Call Transcript: Q4 2025

Alnylam Pharmaceuticals Annual report: Q4 2025

Feb 12, 2026, 8:30 AM EST - 6 months ago

Alnylam Pharmaceuticals Annual report: Q4 2025

Alnylam Pharmaceuticals Earnings release: Q4 2025

Feb 12, 2026, 8:30 AM EST - 6 months ago

Alnylam Pharmaceuticals Earnings release: Q4 2025

Alnylam Pharmaceuticals Slides: Q4 2025

Feb 12, 2026, 8:30 AM EST - 6 months ago

Alnylam Pharmaceuticals Slides: Q4 2025

Alnylam Pharmaceuticals Annual report: Q4 2025

Feb 12, 2026, 8:30 AM EST - 6 months ago

Alnylam Pharmaceuticals Annual report: Q4 2025

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

Feb 12, 2026, 8:00 AM EST - 6 months ago

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

ALNY

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results

Jan 29, 2026, 8:00 AM EST - 7 months ago

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results

ALNY

Alnylam Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:00 PM EST - 8 months ago

Alnylam Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Alnylam Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:00 PM EST - 8 months ago

Alnylam Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact

Jan 11, 2026, 5:00 PM EST - 8 months ago

Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact

ALNY

Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 9:15 AM EST - 8 months ago

Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference

ALNY

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

Dec 19, 2025, 6:25 PM EST - 8 months ago

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

ALNY AMGN ARGX AZN IBB

Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

Dec 17, 2025, 8:00 AM EST - 8 months ago

Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

ALNY

Walmart was too late for a Nasdaq-100 spot — but these 6 stocks made the cut

Dec 13, 2025, 11:04 AM EST - 9 months ago

Walmart was too late for a Nasdaq-100 spot — but these 6 stocks made the cut

WMT ALNY FER MPWR STX WDC

Eight stock picks to play one of the healthiest corners of the market

Dec 11, 2025, 10:37 AM EST - 9 months ago

Eight stock picks to play one of the healthiest corners of the market

ALNY ASND INSM MASI NTRA PODD UNH

Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

Dec 11, 2025, 7:00 AM EST - 9 months ago

Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

ALNY

Alnylam Pharmaceuticals Announces Changes to Board of Directors

Dec 3, 2025, 8:00 AM EST - 9 months ago

Alnylam Pharmaceuticals Announces Changes to Board of Directors

ALNY

CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing

Dec 1, 2025, 3:47 PM EST - 9 months ago

CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing

ALNY CRH VRT ARCC

UK's drug-cost watchdog recommends Alnylam's heart disease drug

Nov 20, 2025, 7:09 PM EST - 9 months ago

UK's drug-cost watchdog recommends Alnylam's heart disease drug

ALNY

Alnylam Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 6:30 AM EST - 9 months ago

Alnylam Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Alnylam Pharmaceuticals Transcript: UBS Global Healthcare Conference 2025

Nov 10, 2025, 10:15 AM EST - 10 months ago

Alnylam Pharmaceuticals Transcript: UBS Global Healthcare Conference 2025

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

Nov 8, 2025, 4:57 PM EST - 10 months ago

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

ALNY

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Nov 4, 2025, 8:00 AM EST - 10 months ago

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

ALNY

jewell69
jewell69 Aug. 24 at 5:34 PM
$ALNY willing 2 pay up for it. trying 2 by 15 at 288.28. as of 1:33 pm edt on 8/24 b a 231.95 x 232.13 lo so far today 228.59 08/14/2026 Sell ALNY ALNYLAM PHARMACEUTICALS 18 $227.80 $0.08 $4,100.32 More 08/13/2026 Buy ALNY ALNYLAM PHARMACEUTICALS 18 $226.12
0 · Reply
MaxDanger
MaxDanger Aug. 24 at 2:40 PM
$ALNY if the hypertension data is good next weekend, this may rocket back to $300+.
0 · Reply
Iskill1
Iskill1 Aug. 24 at 1:24 PM
$QQQ holdings on my radar before the open Bullish: $MDLZ — trend-aligned DB candidate. Watching 63.57 support; structural target remains near 67.08. $CSX — reversal/reclaim watch after Deep Selling Exhaustion. Watching 51.44 and acceptance above 51.75–52. Bearish: $ALNY — the only Tier-2 bearish result from the Nasdaq-100 scan. Rally-fade watch only; the rebound must fail before the bearish thesis becomes active. These are conditional watch candidates, not automatic entries.
0 · Reply
StockBraker
StockBraker Aug. 24 at 12:51 PM
$ALNY https://www.businesswire.com/news/home/20260822840046/en/Alnylam-to-Present-New-Data-Reinforcing-Strength-in-RNAi-Powered-TTR-Silencing-and-Continued-Progress-in-Hypertension-at-ESC-Congress-2026
0 · Reply
ShirleyThames338
ShirleyThames338 Aug. 24 at 9:42 AM
$BIIB $SUNB $EXR $ALNY $TECK Biogen remains focused on neurological therapies, SunBelt-related exposure remains tied to regional financial conditions, Extra Space Storage benefits from self-storage demand, Alnylam advances RNAi medicines, and Teck benefits from copper and metallurgical-coal prices. I'm watching clinical milestones, credit conditions, occupancy, drug launches, and metals prices.
0 · Reply
sampeper
sampeper Aug. 21 at 10:33 AM
$ALNY Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to "Strong-Buy" at BMO Capital Markets https://www.marketbeat.com/instant-alerts/alnylam-pharmaceuticals-nasdaqalny-upgraded-to-strong-buy-at-bmo-capital-markets-2026-08-20/
0 · Reply
akinyo
akinyo Aug. 20 at 10:26 PM
$ALNY Back to $200 so I can pick up 100 more shares pretty please 🥺
0 · Reply
hi_tech_lowlife
hi_tech_lowlife Aug. 20 at 4:30 PM
Biotech Is Booming, But These 2 Stocks Missed the Memo $IBB $MRNA $MRK $INSM $ALNY https://www.benzinga.com/trading-ideas/movers/26/08/61336082/biotech-is-booming-but-these-2-stocks-missed-the-memo
0 · Reply
jewell69
jewell69 Aug. 20 at 4:21 PM
$ALNY trying 2 b 18 232 12:18 pm edt 8/20. we would b paying up for it. recent trade history. soooo lucky we sold b4 earnings, and it fell out of bed. 07/27/2026 Sell ALNY ALNYLAM PHARMACEUTICALS 29 $282.96 $0.18 $8,205.66 08/14/2026 Sell ALNY ALNYLAM PHARMACEUTICALS 18 $227.80 $0.08 $4,100.32 More 08/13/2026 Buy ALNY ALNYLAM PHARMACEUTICALS 18 $226.12 -$4,070.16
0 · Reply
ManuelLemon952
ManuelLemon952 Aug. 20 at 7:38 AM
$BIIB $SUNB $EXR $ALNY $TECK Biogen remains focused on neurological therapies, SunBelt-related exposure remains tied to regional financial conditions, Extra Space Storage benefits from self-storage demand, Alnylam advances RNAi medicines, and Teck benefits from copper and metallurgical-coal prices. I'm watching clinical milestones, credit conditions, occupancy, drug launches, and metals prices.
0 · Reply
notreload_ai
notreload_ai Aug. 19 at 7:18 PM
BMO Capital starts coverage on $ALNY, $ASND, $BMRN, $CATX & more with Outperform ratings and price targets. See full analyst insights and targets. https://notreload.xyz/xy/bmo-capital-initiates-coverage-on-7-biotech-stocks/
0 · Reply
droptopfibonacci
droptopfibonacci Aug. 19 at 4:09 PM
$ALNY $VKTX $MRNA Looks like it might be time to start shopping for some pharma/biotech names with good upside $IBB
2 · Reply
k3vl4r
k3vl4r Aug. 19 at 12:45 PM
The weekend’s most surprising thing? ALNY’s fundamentals hold up even after the reprice. It means the TTR franchise and pipeline optionality are still solid. Keep an eye on the next close for a potential bounce. $ALNY https://app.k3vl4r.com/r/alny-ai-stock-forecast-a46b92eb799478c56498d69c5f85252a?utm_source=x&utm_medium=social&utm_campaign=report_drop&utm_content=ALNY #stocks #StockMarket
0 · Reply
sampeper
sampeper Aug. 17 at 1:39 AM
$ALNY Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing https://www.theglobeandmail.com/investing/markets/stocks/IONS-Q/pressreleases/3874920/why-the-alnylam-sell-off-looks-overdone-and-what-investors-are-missing/
0 · Reply
Olena
Olena Aug. 16 at 5:57 PM
$ALNY profitable, phase 3 this year
0 · Reply
OnlyFibs
OnlyFibs Aug. 15 at 11:19 PM
$ALNY | Alnylam Pharmaceuticals | Healthcare 🧬 Heavy buyer volume flooding into $ALNY as price prints a decisive higher low off its $197.90 macro demand floor! 📈⚡ Alnylam leads global commercialization of RNAi therapeutics powered by its blockbuster AMVUTTRA franchise 🏥 Profitability & Fundamentals: Commercial biopharma powerhouse generating $1.29B Q2 net revenue (+67% YoY) with $3.3B in liquid cash reserves. Technicals: 8h chart highlights a sharp V-bottom higher-low reversal backed by consistent buying volume 🎯 Price reclaimed $220.00 and is coiling for a trendline breakout toward $272.00 and $315.00 supply. Bull Key Levels: $222.00 🐂 🔥 | Confirm: $245.00 🐂 🚀 | Extension: $272.00 🐂 💥 Bear Key Levels: $205.00 🐻 ⚠️ | Confirm: $197.90 🐻 📉 | Extension: $180.00 🐻 🚨 Stop Loss: $201.50 🛑 Targets: $272.00 / $315.00 💰 🍺 OVERALL: 🐂 BULLISH 🐂 #hovdid
0 · Reply
jewell69
jewell69 Aug. 14 at 6:17 PM
$ALNY I know, I know 30 bucks. I get it. short leash. very very very rare disease 08/14/2026 Sell Edit cost basis method ALNY ALNYLAM PHARMACEUTICALS 18 $227.80 $0.08 $4,100.32 More 08/13/2026 Buy ALNY ALNYLAM PHARMACEUTICALS 18 $226.12 -$4,070.16
0 · Reply
MoneyMacG
MoneyMacG Aug. 13 at 11:03 PM
$ALNY nice `
0 · Reply
Fingerlickengood
Fingerlickengood Aug. 13 at 7:17 PM
$CDXS It's quiet possible Aurisco is indirectly using Codexis' technology through a relationship they formed years ago with Porton Pharma of China under John Nichols leadership. I think it's VERY compelling that Aurisco has obtained licensing to manufacture both Inclisiran and Vutrisiran from $ALNY . Now USFDA has approved their CDMO facility to manufacture both for the 'generic market'. https://www.pharmafocusasia.com/interviews/codexis-porton-partnership
0 · Reply
jewell69
jewell69 Aug. 13 at 6:00 PM
$ALNY trying 2 by 18 at 226.12. yes u read it correctly. thing fell tons 3 weeks ago. beware ! potential patient population is only 38,000 people in the usa. sort of reminds me of $SRPT Date Transaction Type Symbol Description Quantity Price Fees & Comm Amount 07/27/2026 Sell ALNY ALNYLAM PHARMACEUTICALS 29 $282.96 $0.18 $8,205.66 More 07/24/2026 Sell ALNY ALNYLAM PHARMACEUTICALS 11 $271.92 $0.06 $2,991.06 More 07/22/2026 Buy ALNY ALNYLAM PHARMACEUTICALS 11 $265.10 -$2,916.10 More 07/21/2026 Buy ALNY ALNYLAM PHARMACEUTICALS 8 $272.14 -$2,177.12 More 07/20/2026 Sell ALNY ALNYLAM PHARMACEUTICALS 8 $272.73 $0.04 $2,181.80 More 07/17/2026 Buy ALNY ALNYLAM PHARMACEUTICALS 8 $271.80 -$2,174.40
1 · Reply
ConsistentSpike
ConsistentSpike Aug. 13 at 5:31 PM
$ALNY https://www.tipranks.com/news/raymond-james-is-betting-big-on-these-2-strong-buy-stocks
0 · Reply
SahreIn
SahreIn Aug. 12 at 8:26 PM
$ALNY nice price movement .. should break 230 in a week
0 · Reply